Lv31
268 积分 2022-11-25 加入
Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate
3小时前
待确认
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4小时前
已完结
Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
4小时前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4小时前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
3天前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
3天前
已完结
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy
13天前
已完结
A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy
13天前
已完结
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
19天前
已完结
Therapeutic B-cell depletion: Mechanisms, clinical applications, and implications for secondary immunodeficiency
1个月前
已完结
皖公网安备34019202002308
